The Salmonella effector SpvD is a cysteine hydrolase with a serovar-specific polymorphism influencing catalytic activity, suppression of immune responses, and bacterial virulence


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/70272/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
The Salmonella Effector SpvD Is a Cysteine Hydrolase with a Serovar-specific Polymorphism Influencing Catalytic Activity, Suppression of Immune Responses, and Bacterial Virulence*[^5]

Many bacterial pathogens secrete virulence (effector) proteins that interfere with immune signaling in their host. SpvD is a Salmonella enterica effector protein that we previously demonstrated to negatively regulate the NF-κB signaling pathway and promote virulence of S. enterica serovar Typhimurium in mice. To shed light on the mechanistic basis for these observations, we determined the crystal structure of SpvD and show that it adopts a papain-like fold with a characteristic cysteine-histidine-aspartate catalytic triad comprising Cys-73, His-162, and Asp-182. SpvD possesses an in vitro deconjugative activity on aminoluciferin-linked peptide and protein substrates in vitro. A C73A mutation abolished SpvD activity, demonstrating that an intact catalytic triad is required for its function. Taken together, these results strongly suggest that SpvD is a cysteine protease. The amino acid sequence of SpvD is highly conserved across different S. enterica serovars, but residue 161, located close to the catalytic triad, is variable, with serovar Typhimurium SpvD having an arginine and serovar Enteritidis a glycine at this position. This variation affected hydrolytic activity of the enzyme on artificial substrates and can be explained by substrate accessibility to the active site. Interestingly, the SpvD[^1] variant more potently inhibited NF-κB-mediated immune responses in cells in vitro and increased virulence of serovar Typhimurium in mice. In summary, our results explain the biochemical basis for the effect of virulence protein SpvD and demonstrate that a single amino acid polymorphism can affect the overall virulence of a bacterial pathogen in its host.

Salmonella enterica serovars Typhimurium and Enteritidis are broad host range intracellular bacterial pathogens causing gastrointestinal disease in humans and a typhoid-like systemic infection in certain mouse strains. Their virulence depends on the activity of two type III secretion systems (T3SSs),[^2] encoded by the pathogenicity islands Salmonella pathogenicity island 1 (SPI-1) and SPI-2 that enable translocation of effector proteins into host cells. The majority of effector proteins are encoded on the bacterial chromosome, but some are present on the pSLT virulence plasmid (1). An important virulence determinant of the pSLT plasmid is the Salmonella plasmid virulence locus (spv) (2–5), which comprises the spvABCD operon and its upstream regulator spvR (6). SpvB is an ADP ribosyl transferase that depolymerizes F-actin (7), and SpvC is a phosphothreonine lyase that inhibits mitogen-activated protein kinase signaling (8, 9).

### Results

SpvD Adopts a Papain-like Fold—To gain insight into the function of SpvD, we attempted to determine its crystal structure. After unsuccessful crystallization of wild-type SpvD, we obtained crystals of SpvD in which its predicted surface cys-
### SpvD Structure and Activity

#### Table 1

<table>
<thead>
<tr>
<th>Data collection and refinement statistics</th>
<th>SpvD&lt;sup&gt;D37/CS5&lt;/sup&gt;/JAC</th>
<th>SpvD&lt;sup&gt;D37/CS5/SIRAS&lt;/sup&gt;</th>
<th>SpvD (Au SIRAS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wavelength (Å)</td>
<td>0.97625</td>
<td>0.97949</td>
<td>0.92000</td>
</tr>
<tr>
<td>Space group</td>
<td>P21</td>
<td>P21</td>
<td>P21</td>
</tr>
<tr>
<td>Cell dimensions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a, b, c (Å)</td>
<td>42.7, 51.8, 47.27</td>
<td>44.5197, 47.22</td>
<td>43.84, 52.11, 47.38</td>
</tr>
<tr>
<td>α, β, γ (%)</td>
<td>90, 107.41, 90</td>
<td>90, 107.7, 90</td>
<td>90, 107.84, 90</td>
</tr>
<tr>
<td>Resolution range (Å)</td>
<td>51.81–1.48 (1.56–1.48)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>51.97–1.60 (1.69–1.60)</td>
<td>41.73–2.25 (2.31–2.25)</td>
</tr>
<tr>
<td>Reflections, total</td>
<td>195,684 (21,204)</td>
<td>156,479 (23,249)</td>
<td></td>
</tr>
<tr>
<td>Reflections, unique</td>
<td>33,404 (46,144)</td>
<td>26,737 (3,893)</td>
<td></td>
</tr>
<tr>
<td>R&lt;sub&gt;merge&lt;/sub&gt; (%)</td>
<td>12.1 (2.1)</td>
<td>10.4 (1.9)</td>
<td>18.1 (3.8)</td>
</tr>
<tr>
<td>Complete (%)</td>
<td>99.1 (94.1)</td>
<td>99.4 (99.2)</td>
<td>100 (60.8)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Multiplicity</td>
<td>5.9 (4.6)</td>
<td>5.9 (6.0)</td>
<td>6.4 (4.2)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Refinement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R&lt;sub&gt;merge&lt;/sub&gt;/R&lt;sub&gt;free&lt;/sub&gt; (%)</td>
<td>16.96/20.15</td>
<td>16.32/19.73</td>
<td></td>
</tr>
<tr>
<td>No. of atoms</td>
<td>1,556</td>
<td>1,713</td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>182</td>
<td>205</td>
<td></td>
</tr>
<tr>
<td>R&lt;sub&gt;merge&lt;/sub&gt;/R&lt;sub&gt;free&lt;/sub&gt; (%)</td>
<td>22.07</td>
<td>19.96</td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>17.18</td>
<td>28.19</td>
<td></td>
</tr>
<tr>
<td>r.m.s.d. bond length (Å)</td>
<td>30.76</td>
<td>30.61</td>
<td></td>
</tr>
<tr>
<td>r.m.s.d. bond angle (°)</td>
<td>0.0154</td>
<td>0.0164</td>
<td></td>
</tr>
<tr>
<td>Ramachandran favored/outliers (%)</td>
<td>1.573</td>
<td>1.410</td>
<td></td>
</tr>
<tr>
<td></td>
<td>98.9/0.9</td>
<td>98.1/0.5</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Values in parentheses correspond to the highest resolution shell.

<sup>b</sup> Completeness and multiplicity values given for anomalous data.

The amino acid sequence of SpvD varies among serovars of *Salmonella enterica* (21). We carried out a protein BLAST search using the amino acid sequence of *S. typhimurium* 14028 SpvD. This confirmed previously described polymorphisms and found sequences homologous to SpvD in other bacterial species such as *Pseudomonas psychrophila* and *Providencia burhodogranaria* (supplemental Fig. S1). Within the broad host range serovars of *S. enterica*, Enteritidis and Typhimurium, there are only two positions that consistently vary in amino acid composition (154 and 161) (Fig. 3A and supplemental Fig. S1). Within Typhimurium serovars, an alanine is encoded at position 154, and an arginine is encoded at position 161. In contrast, all Enteritidis serovars sequenced to date have either alanine or valine at position 154 and glycine at position 161 (Fig. 3A). Both residues are in close proximity to the catalytic triad, and their side chains contribute to the structure of the active site groove (Fig. 3B, blue and green sticks). Positions 154 and 161 of SpvD homologues in species other than *Salmonella* are mainly occupied by small hydrophobic residues (leucine and isoleucine at 154 and glycine and alanine at 161; supplemental Fig. S1). Within *Salmonella*, the Gly-161 polymorphism appears to be unique to Enteritidis, Abortus-equii, and Bovismorfbicans serovars as all others (Typhimurium, Dublin, Paratyphi C, Gallinarum, Pullorum, and Choleraesuis) contain arginine at this position (supplemental Fig. S1). We used a variety of assays to determine the potential enzymatic activity of SpvD. Structural similarity to ubiquitin hydrolases suggested that SpvD could be a deubiquitinase. In a screen that utilizes a C-terminal peptide of ubiquitin (RLRGG) fused to aminoluciferin for detection of ubiquitin and ubiquitin-like proteases (DUB-Glo™ protease assay; Promega), we found that SpvD, like the known *Salmonella* deubiquitinase (DUB) SseL (22, 23), produced a stable and specific luminescence signal indicative of substrate hydrolysis. Consistent with the crystal structure, SpvD hydrolytic activity was dependent on cysteine 73 of its putative catalytic triad (Fig. 3C). Interestingly, conversion of the SpvD sequence to that of the Enteritidis...
strains increased the activity observed in the DUB-Glo™ protease assay (Fig. 3, C and D). At the highest concentration tested, the most active variant, SpvDA154/G161, produced over 10 times more luminescence signal than SpvDA154/R161, 5 h after the start of the assay (Fig. 3, C and D). In this assay, protease and luciferase activities normally reach a steady state so that a maximal signal is reached after 30 min and maintained for several hours. In contrast to SseL and SpvDA154/R161, the luminescence signal produced by the SpvDA154/G161 and SpvDV154/G161 variants did not stabilize after 30 min but continued to increase up to 5 h (Fig. 3D). SpvDV154/G161 had an intermediate activity in the DUB-Glo™ assay, in between that of SpvDA154/R161 and SpvDV154/G161 (Fig. 3C and D). Due to the more pronounced effect of the variation at position 161, we focused further studies on this polymorphism, maintaining alanine at position 154. To explain why the Gly-161 polymorphism leads to greater activity, we crystallized an inactive (C73A) form of the variant in the presence of RLRGG-AML substrate. Although density
for the RLRGG-AML substrate was not observed, we were able to build additional loops (two of them near the active site) that were disordered in the previously obtained SpvD4CS/R161 structure (supplemental Fig. S2). To map a potential ligand binding site on SpvD, we superimposed the catalytic triad with that of the UCH-L3 ubiquitin hydrolase crystallized in complex with ubiquitin (Fig. 3E). The position of the superimposed five C-terminal amino acids of ubiquitin (RLRGG) is unobstructed in the SpvD4CS/G161/C73A variant (Fig. 3E, right), whereas in SpvD4CS/R161, binding would be impeded by the side chain of Arg-161, which restricts access to the active site (Fig. 3E, left). Therefore, the Arg-161 side chain could have an inhibitory steric or regulatory role in the activity of SpvD. These results demonstrate that SpvD is a hydrolytic enzyme with a catalytic triad that is characteristic of papain-like proteases. As the DUB-Glo™ protease assay detects ubiquitin and ubiquitin-like proteases, we then assayed SpvD variants using full-length ubiquitin-AML as a substrate. As expected, the positive control SseL was active at all concentrations tested (1/100,000, 5/100,000, and 25/100,000 M; Fig. 4A). Surprisingly, the only SpvD variant that produced a specific, Cys-73-dependent signal was SpvDA154/R161 (Fig. 4A and B). The luminescent signal produced by SseL decreased over time from an initial level of 100-fold above background, indicating substrate depletion (Fig. 4B). In contrast SpvDA154/R161...
FIGURE 4. SpvD<sup>R161</sup> was active on a ubiquitin-AML substrate. A, a modification of the DUB-Glo<sup>TM</sup> assay with RLRGG substrate replaced by a full-length ubiquitin conjugated to aminoluciferin (Ub-AML). A representative assay result is shown. B, Ub-AML deconjugation assay over time measured for the highest concentration (25 μM) of the tested proteins. Signals were taken every 15 min. C, in vitro deubiquitination assay done with 5 μM of either SseL (top) or SpvD<sup>A154/R161</sup> (bottom). Diubiquitin linkages were incubated with tested proteins for 0, 30, and 60 min followed by SDS-PAGE separation and Coomassie staining. Detectable cleavage product in the form of a single ubiquitin band is indicated with an arrow. D, AMC deconjugation assay using ubiquitin-AMC (yellow), ISG15-AMC (blue), NEDD8-AMC (orange), SUMO1-AMC (green), and SUMO2-AMC (red). Results are shown as mean fluorescence values with S.D. of three technical repeats obtained 1 h after start of the experiment. Isopeptidase T was used as a positive control for ubiquitin-AMC and ISG15-AMC. SENP2 was used as a control protease for SUMO1-AMC and SUMO2-AMC substrates, whereas NEDP1 was used in case of NEDD8-AMC.
produced a level of luminescence that was ~10-fold above background and remained relatively constant over the course of the assay. Interestingly, in this assay both SpvD\textsubscript{A154/G161} and SpvD\textsubscript{A154/G161} displayed virtually no activity (Fig. 4, A and B). To test if SpvD\textsubscript{A154/R161} has linkage-specific deubiquitinating activity, diubiquitin molecules linked by seven different lysine residues or methionine M1 were tested for cleavage. SseL cleaved isopeptide molecules linked by Lys-11, Lys-48, and Lys-63 (Fig. 4C, top), but SpvD\textsubscript{A154/R161} had no detectable activity on any of the substrates (Fig. 4C, bottom). To test if SpvD\textsubscript{A154/R161} has activity against other ubiquitin-like proteins, we used substrates comprising full-length ubiquitin or four ubiquitin-like proteins (SUMO1, SUMO2, NEDD8, and ISG15) C-terminally linked to 7-amino-4-methylcoumarin (AMC). SpvD\textsubscript{A154/R161} had no detectable activity on any of these substrates, whereas SseL produced a specific fluorescent signal with ubiquitin-AMC as a substrate (Fig. 4D).

Inhibition of the NF-κB Pathway by SpvD Is Dependent on Cys-73 and Is Affected by Variation at Residue 161—

We showed previously that SpvD inhibits the NF-κB signaling pathway (11). To investigate the influence of the amino acid side chain at position 161 and the requirement for the putative catalytic cysteine (Cys-73) on the anti-inflammatory activity of SpvD, HEK 293 cells were co-transfected with a reporter plasmid encoding luciferase under the control of an NF-κB promoter and a plasmid encoding either myc alone (pRK5 vector), myc-SpvD variants with alanine at position 154, or GFP-tagged positive control inhibitory proteins: *Salmonella* SseK3 (24) and NF-κB inhibitor α (IkBα) S32A/S36A mutant protein (25). Luciferase activity was measured 16 h after stimulation with TNFα or phorbol 12-myristate 13-acetate (PMA) and normalized to that of non-stimulated cells. TNFα and PMA caused 25- and 20-fold increases in NF-κB activation, respectively (Fig. 5, A and B). Expression of tagged proteins was confirmed by Western blotting (Fig. 5C). SseK3 is an effector that is known to inhibit the NF-κB pathway upon TNFα stimulation (14). In this assay it inhibited the reporter activity by 92% (Fig. 5A). After TNFα stimulation, SpvD\textsubscript{A154/R161} and SpvD\textsubscript{A154/G161} reduced NF-κB fold activation by 36 and 41%, respectively, and these effects were dependent on Cys-73 (Fig. 5A). There was no significant difference in the level of NF-κB inhibition between the Arg-161 and Gly-161 variants (Fig. 5A).
However, after stimulation with PMA, both the positive control protein IκBα S32A/S36A and SpvD A154/G161 inhibited the NF-κB pathway to a similar level (Fig. 5B), whereas SpvD A154/R161 had a much smaller effect. Therefore, the increased hydrolase activity of SpvD A154/G161 over SpvD A154/R161 in the DUB-Glo™ protease assay (Fig. 3C) correlates with an enhanced ability of SpvD G161 to inhibit the NF-κB inflammatory pathway in cells stimulated with PMA.

Higher In Vitro Deconjugative and Anti-inflammatory Activities of Naturally Occurring SpvD Variant Correlate with Salmonella Virulence in Vivo—Salmonella strains lacking SpvD were shown to be attenuated for growth in mice when compared with the wild-type strain (10, 11). Having detected different in vitro deconjugation and anti-inflammatory activities of SpvD variants, we tested if the side chain at position 161 within the SpvD active site influences Salmonella growth in vivo. First, we confirmed bacterial translocation of C-terminal double-hemagglutinin (HA)-tagged SpvD A154/G161 over SpvD A154/R161 in iBMDMs, showing that catalytic triad mutations did not affect effector delivery (Fig. 6). Mice were then inoculated by intraperitoneal injection with a mixture of equivalent cfu of ΔspvD mutant strain and chloramphenicol-resistant ΔspvD mutant strains harboring various pACYC184-based complementation plasmids (Fig. 7). After 72 h of infection, bacteria were quantified after plating spleen homogenates on LB agar medium and LB agar medium containing chloramphenicol to distinguish the strains. The competitive index (CI) of ΔspvD mutant and ΔspvD mutant harboring an empty pACYC184 plasmid (EV) was 0.34 ± 0.04, showing that the presence of pACYC184 incurred a fitness cost (Fig. 7). When mixed with ΔspvD strains carrying pACYC184 encoding either SpvD A154/R161 or SpvD A154/G161, the CI of the ΔspvD mutant strain dropped from 0.34 to −0.12 and −0.39, respectively (Fig. 7). Interestingly, the ΔspvD mutant was more efficiently out-competed by the SpvD A154/G161 strain compared with the SpvD A154/R161 strain, demonstrating that the more active SpvD A154/G161 variant is more potent in complementing the ΔspvD mutation than SpvD A154/R161 (Fig. 7). When mixed with ΔspvD strains carrying plasmids encoding the C73A mutant versions of SpvD, the ΔspvD strain had CIs of 0.15 ± 0.14 and 0.32 ± 0.08 for SpvD A154/R161/C73A and SpvD A154/G161/C73A, respectively) similar to the CI of the ΔspvD strain mixed with ΔspvD strain harboring empty pACYC184 plasmid (Fig. 7). Therefore, the ability of both SpvD A154/R161 and SpvD A154/G161 to complement the virulence defect was dependent on a functional catalytic triad.

Discussion

In this work we have determined the structure of SpvD, a S. typhimurium SPI-2 T3SS effector protein that inhibits the
SpvD Structure and Activity

![Graph showing SpvD Structure and Activity](image)

NF-κB signaling pathway (11). Structurally, SpvD can be classified as belonging to the CA clan of cysteine proteases that contains papain and related proteases (MEROPS peptidase database). A hallmark of this clan is a CHD (or CHN) catalytic triad, which in the case of SpvD is composed of Cys-73, His-162, and Asp-182. Using a DUB-Glo™ assay, we showed that SpvD is an enzyme with deconjugative activity. Taken together, the results of our experiments strongly suggest that SpvD acts as a protease. Due to the chemical nature of the DUB-Glo™ substrate (aminoluciferin fused to the C terminus of an RLRGG peptide), the DUB-Glo™ assay would potentially not only detect deubiquitinases or ubiquitin-like proteases but any protease that recognizes and cleaves after a sequence similar to GG.

In all the assays tested (DUB-Glo™, NF-κB inhibition, virulence in mouse) the activity of SpvD was abolished by a C73A mutation, demonstrating the necessity of an intact catalytic triad. Despite being less active in the DUB-Glo™ assay, SpvDA154/R161 was the most active SpvD variant in the Ub-AML deconjugation assay. This suggested that SpvDA154/R161 might be a DUB or ubiquitin-like protease. However, we were unable to obtain evidence for this in subsequent AMC deconjugation and in vitro deubiquitination assays. When compared with the Typhimurium SpvDA154/R161 variant, SpvD with a single polymorphism (Gly-161) was more potent in (i) the DUB-Glo™ protease assay, (ii) inhibition of the NF-κB luciferase assay in PMA-stimulated cells, and (iii) virulence in mice. The observation that SpvDA154/G161 is more potent at inhibiting NF-κB signaling than SpvDA154/R161 in PMA- but not TNFα-stimulated HEK293 cells might help guide the identification of its substrate. PMA mimics diacylglycerol in stimulating NF-κB through activation of protein kinase C (26). Therefore, our results suggest that the more active SpvD variant targets a diacylglycerol-stimulated branch of NF-κB pathway. There are very few descriptions of single amino acid polymorphisms influencing the potency of bacterial effectors. A naturally occurring polymorphism within S. typhimurium Ssel at position 103 was shown to affect binding to the cell migration adaptor protein TRIP6 in a yeast two-hybrid assay and bacterial dissemination in mice (27). However, the position of the Ssel polymorphism in relation to the catalytic site is unknown as only partial Ssel (amino acids 145–313) structure is currently available (15). The SpvD polymorphism that we have investigated here is in very close vicinity of the catalytic triad. Depending on the substrate used in vitro, the Arg-161 or Gly-161 variant displayed greater potency. However, the Gly-161 variant conferred stronger inhibition of a PMA-stimulated NF-κB reporter and greater virulence of Salmonella in mice. Regardless of the identity of the physiological substrate for hydrolytic activity of SpvD, it is remarkable that a single amino acid substitution that alters hydrolytic potency can influence the complex process of virulence in a host. The fact that the SpvDR161 variant is present in all Salmonella serovars except Enteritidis, Bovismoribicans, and Abortus-equini is intriguing. It is possible that SpvDR161 has gained a different substrate specificity that is not related to NF-κB signaling. Collectively, our results indicate SpvD is a papain-like hydrolase that functions through a cysteine-mediated hydrolysis reaction to inhibit gene expression from NF-κB promoters. Furthermore, we demonstrate that a natural SpvD polymorphism significantly affects virulence and NF-κB inhibition in PMA-stimulated cells, leading us to hypothesize that the substrate hydrolyzed by SpvDG161 might be part of a signaling pathway involving protein kinase C.

Experimental Procedures

**Bacterial Strains and Plasmids**—Bacterial strains and plasmids used in this study are listed in supplemental Table S1. The Salmonella strains were grown in Luria Bertani (LB) medium at 37 °C with shaking and supplemented with ampicillin (100 μg/ml) or chloramphenicol (34 μg/ml) as appropriate. Complementation plasmids (pACYC184 or pWSK29) containing non-tagged or double HA-tagged spvD were obtained using restriction enzyme clon-
Site-directed mutagenesis of SpvD was performed by inverse PCR using pRK5-myc-SpvD<sub>A154/R161</sub> vector as DNA template.

**Protein Production**—For crystallography, SpvD<sub>C73A/G161</sub> and SpvD<sub>C73A/G161</sub> were expressed with a precision protease-cleavable N-terminal His<sub>6</sub> tag from pHiSH, a pET15b-derived vector (28) in PC2 cells (29). Cultures were grown in Terrific Broth or LB to an A<sub>600</sub> of 0.8 at 37 °C and induced with 0.5 mM isopropyl-1-thio-β-D-galactopyranoside for 16–20 h at 20 °C. Depending on the protein fusion tag, proteins were purified to apparent homogeneity using either nickel- or glu-tathione-based affinity chromatography as described previously (30). Cultures were grown in PKC cells (28) in PC2 cells (29). Cultures were grown in Terrific Broth or LB to an A<sub>600</sub> of 0.8 at 37 °C and induced with 0.5 mM isopropyl-1-thio-β-D-galactopyranoside for 16–20 h at 20 °C. Cells were lysed by sonication in 50 mM Tris/Cl, pH 7.5, 500 mM NaCl, 20 mM imidazole, 0.5 mM phenylmethylsulfonyl fluoride. After clarification by centrifugation, the lystate was mixed with nickel-nitrilotriacetic acid resin for 1 h at 4 °C. The resin was extensively washed with 50 mM Tris/Cl, pH 7.5, 500 mM NaCl, and 20 mM imidazole, and SpvD was eluted with 50 mM Tris/Cl, pH 7.5, 500 mM NaCl, and 500 mM imidazole. The His tag was removed by the addition of 10 mM dithiothreitol and HRV 3C protease at a ratio of 1 mg protease to 30 mg SpvD and overnight incubation at 4 °C. The SpvD solution was loaded onto a Superdex75 gel filtration column (GE Healthcare) pre-equili-brated in 50 mM Tris/Cl, pH 7.5, 150 mM NaCl, and 10 mM β-mercaptoethanol. For biochemical analyses, GST-SseL, SpvC-His<sub>6</sub>, and SpvD<sub>A154/R161</sub>-His<sub>6</sub> proteins were purified from previously generated pGEX and pET22b vectors (9, 11, 22). Variants of SpvD were made using site-directed mutagenesis, and their protein-coding DNA sequences were ligated into pET22b using identical restriction sites. Protein was expressed in Escherichia coli BL21(DE3) cells that were grown to an A<sub>600</sub> of 0.8–1.0 at 37 °C and induced with 1 mM isopropyl-1-thio-β-D-galactopyranoside for 16–20 h at 20 °C. Depending on the protein fusion tag, proteins were purified to apparent homogeneity using either nickel- or gluta-thione-based affinity chromatography as described previously (9, 22).

**DUB-Glo<sup>TM</sup> and Ub-AML Assays**—Purified SpvC, SseL, and SpvD proteins were each used in the DUB-Glo<sup>TM</sup> assay at 1, 5, and 25 μM concentrations. The DUB-Glo<sup>TM</sup> assay was performed using the manufacturer’s instructions (Promega). Briefly, 50 μl of 2, 10, and 50 μM of tested proteins diluted in reaction buffer (50 mM HEPES, pH 7.4, 50 mM NaCl, 0.5 mM EDTA, 10 mM DTT) was mixed with 50 μl of RLLGG-AML substrate containing luciferase reporter enzyme. Luciferase activity was measured at 22 °C every 15 min up to 5 h with an Infinite M200Pro plate reader (Tecan). In a modification of the assay, 40 μM RLLGG-AML was replaced with 1 μM Ub-AML, whereas the remaining buffer composition and luciferase enzyme remained unchanged.

**AMC Deconjugation Assay**—SseL, SpvC, and SpvD<sub>A154/R161</sub> proteins were incubated with 1 μM concentrations of ubiquitin-, SUMO1-, SUMO2-, ISG15-, and NEDD8-AMC (Boston Biochem) in 50 mM HEPES, pH 8.0, and 1 mM DTT. Liberation of AMC at 22 °C was measured after 1 h of incubation using Infinite M200Pro plate reader (Tecan; excita-tion/emission wavelengths 380/460 nm).

**In Vitro Deubiquitination Assay**—A panel of M1 linear Lys-6-, Lys-11-, Lys-27-, Lys-29-, Lys-33-, Lys-48-, and Lys-63-linked diubiquitin chains was acquired from UbiQ. The reaction mixture contained 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM EDTA, 5 mM DTT, and 5 μM diubiquitin chains. Diubiquitin hydrolysis reactions were performed at 37 °C by adding 5 μM concentrations of either SseL (positive control) or SpvD. The assay was started by mixing the tested protein and diubiquitin solutions, and 10-μl aliquots were taken at the indicated time points. The reaction was resolved on 4–12% SDS-PAGE gradient gels run in MES buffer (Invitrogen) and stained with Coomasie Brilliant Blue R-250 (Bio-Rad).

**Antibodies**—Immunofluorescence analysis was done using goat anti-Salmonella (CSA-1, Kirkegaard and Perry Laboratories) and mouse anti-HA (HA11, Covance) antibodies. Immunoblotting of tagged proteins was performed using 9e10 (Roche Applied Science) and GFP (Life Technologies) antibodies. Tubulin was probed with E7 antibody (Developmental Studies Hybridoma Bank).

**Cell Culture**—HEK293 cells cultured in this study were obtained from the European Collection of Animal and Cell Cultures (Salisbury, UK) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies) supplemented with 10% fetal calf serum (FCS) (PAA Laboratories or Sigma) at 37 °C in 5% CO<sub>2</sub>. Bone marrow-derived macrophages (BMDM) were infected with the v-myc/v-raf expressing J2 retrovirus (30) and differentiated in 20% LCM (1.929 cell (ATCC) conditioned medium). Cells were then maintained in DMEM (Sigma), 10% FCS, 20% LCM, and 1 mM sodium pyruvate at 37 °C, 5% CO<sub>2</sub>.

**Crystallization and Structure Determination**—SpvD<sup>AC5</sup> and SpvD<sup>AC5/C73A/G161</sup> proteins at 9 mg/ml in 50 mM Tris/Cl, pH 7.5, 50 mM NaCl, and 10 mM β-mercaptoethanol were crystallized by vapor diffusion in hanging drops against a reservoir of 100 mM Tris/Cl, pH 7.5, 200 mM NaCl, 22% PEG3350 at 4 °C. Two different crystal morphologies grew in the drops, and seeding was used to propagate the three-dimensional crystal form, which diffracted consistently to high resolution. SpvD<sup>AC5</sup> crystals were transferred to a cryoprotectant solution of 100 mM Tris/Cl, pH 7.5, 200 mM NaCl, 22% PEG3350, and 20% glycerol and flash-frozen in liquid nitrogen, and diffraction data were collected to 1.48 Å on beamline 103 at Diamond Light Source (Oxfordshire, UK) (Table 1). Anomalous data were collected on I04-1 at Diamond Light Source from a crystal soaked for 1 h in 100 mM Tris/Cl, pH 7.5, 200 mM NaCl, 22% PEG3350, and 20% glycerol, 1 mM KAuCl<sub>4</sub>. SpvD<sup>AC5/C73A/G161</sup> crystals were grown as above and transferred stepwise with increasing concentrations of dimethyl sulfoxide (DMSO) and Z-RLLGG-amino-luciferin (Promega) to a final solution of 100 mM Tris/Cl, pH 7.5, 200 mM NaCl, 22% PEG3350, 25% DMSO, 1 mM Z-RLLGG-aminoluciferin before flash-freezing and collecting data at Diamond Light Source beamline I02. Native data were integrated in Mosfim (31) and merged in Scala (32) of the CCP4 suite (33), and anomalous data were processed with the xia2 pipeline using XDS and XSCALE (34–37). The structure was solved by single isomorphous replacement with anomalous scattering in Phenix using the AutoSol wizard (38, 39) with one site and an initial figure of merit of 0.35. The initial structure was built by Phenix AutoBuild wizard (40) and refined using Refmac and Phenix (38, 41) iterated with manual model building in Coot (42). Structures were refined to final resolutions of 1.48 Å (Arg-161) and 1.60 Å (Gly-161) with good geometry (Table 1). The coordinates and structure factors of the structures of SpvD Structure and Activity
SpvD Structure and Activity

SpvD<sup>C5/S/R161</sup> and SpvD<sup>C5/C73A/G161</sup> have been deposited in the protein data bank with PDB codes 5LQ6 and 5LQ7, respectively.

**DNA Transfection**—HEK293 cells were seeded in 24-well plates at a concentration of 2 × 10<sup>4</sup> cells/well 24 h before transfection with Lipofectamine 2000 (Life Technologies) following the manufacturer’s protocol. Cells were used 24 h after transfection.

**Fixation, Permeabilization, Fluorescence Labeling, and Microscopy**—All samples were fixed in 3% paraformaldehyde. Permeabilization was done in 0.2% Triton X-100 together with incubation with primary antibodies. All antibodies were diluted to the appropriate concentrations in PBS containing 10% horse serum and 0.2% Triton-X100. The coverslips were washed once in PBS, incubated with primary antibodies for 2 h, washed 3 times in PBS, and incubated with secondary antibodies and nucleic acid dye DAPI (Thermo Fisher) for 1 h. Coverslips were washed and mounted onto glass slides using Mowiol mounting medium. Cells were analyzed using a confocal laser-scanning microscope (LSM710; Zeiss GmbH).

**Luciferase Reporter Assay**—HEK293 cells were seeded at a density of 5 × 10<sup>4</sup> cells per well in a 24-well plate 24 h before transfection. Cells were transfected for 24 h with 50 ng of luciferase reporter plasmid (NF-κB dependent luciferase reporter plasmid), 30 ng of pTK-Renilla luciferase, and 500 ng of expression vectors (SpvD, SseK3, IκBα<sup>S32A/S36A</sup> or pRK5 vector alone). Cells were then incubated either with 10 ng/ml TNFα or 100 nM PMA for 16 h and harvested in 100 μl of passive lysis buffer (Promega). Luciferase activity was measured using the Dual Luciferase reporter assay system (Promega) and Infinite M200Pro plate reader (Tecan) and normalized according to Renilla luciferase intensity. The data presented are from at least four independent experiments.

**Mice Infections**—To prepare the inocula, bacteria were first grown overnight in LB broth and then subcultured at a dilution of 1:100 for a further 2 h. Cultures were diluted to a concentration of 5 × 10<sup>5</sup> cfu/ml in physiological saline. For CI measurements, bacterial cultures were mixed for intraperitoneal inoculation (0.2 ml per mouse). Viable bacteria in inocula were quantified by dilution and plating onto LB agar plates with appropriate antibiotics to distinguish between strains. Female C57BL/6 mice (Charles River, 6–8 weeks) were sacrificed at 3 days post inoculation. The spleens were removed aseptically and homogenized in distilled water by mechanical disruption. Serial dilutions were plated on LB agar for cfu enumeration. Strains were distinguished by differential counting or replica plating on antibiotic-supplemented plates. For each mouse, the CI was calculated by dividing the output ratio (i.e. strain a versus strain b) divided by the input ratio. The log CI values were used to calculate means and for statistical analyses.

**Ethics Statement**—Animals were used in accordance with UK Home Office regulations. The Imperial College Animal Welfare and Ethical Review Body (AWERB) committee approved the project license for animal research (70/7768). The following people formed the panel: Applicant Scientist, CBS site manager/NACWO, NVS, peer scientist, and a lay person.

**Statistical Analysis**—All results are reported as the mean ± S.E. Statistical analyses were done using one-tailed paired Student’s t test or ANOVA followed by Bonferroni’s multiple comparison test. Differences denoted in the text as significant represent p values lower than 0.05.

**Author Contributions**—G. J. G., S. A. H., and D. W. H. designed the project. N. R. and Y. Y. designed and purified SpvD<sup>C5</sup> Y. Z., M. P., and S. A. H. performed crystal structures determination. J. N. P. and D. K. provided the amino acid sequence and structural insights. G. J. G. performed SpvD activity assays, immunofluorescence, and mouse infections. G. J. G., S. A. H., and D. W. H. wrote the paper with contributions from the other authors.

**Acknowledgments**—We thank colleagues from Centre for Molecular Bacteriology and Infection for critical reading of the manuscript and Steve Matthews for helpful discussions throughout the project. We are grateful to Izabela Glegola-Madejska for technical support with mouse infections. We thank Felix Randow and Regina Günster for the luciferase reporter, SseK3, and IκBα<sup>S32A/S36A</sup> plasmids. We acknowledge the help of staff from Diamond Light Sourcebeamlines I03 and I02 with data collection.

**References**

The *Salmonella* Effector SpvD Is a Cysteine Hydrolase with a Serovar-specific Polymorphism Influencing Catalytic Activity, Suppression of Immune Responses, and Bacterial Virulence

Grzegorz J. Grabe, Yue Zhang, Michal Przydacz, Nathalie Rolhion, Yi Yang, Jonathan N. Pruneda, David Komander, David W. Holden and Stephen A. Hare


Access the most updated version of this article at doi: 10.1074/jbc.M116.752782

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2016/10/27/M116.752782.DC1

This article cites 42 references, 10 of which can be accessed free at http://www.jbc.org/content/291/50/25853.full.html#ref-list-1